Shares of Moderna jumped 3.81% to $152.60 at 13:49 EST on Tuesday, following last session’s upward trend. NASDAQ Composite is rising 0.17% to $13,658.84, after five successive sessions in a row of gains. This seems, at the moment, a somewhat positive trend trading session today.

Moderna’s last close was $147.00, 16.97% under its 52-week high of $178.50.

News about Moderna today

Moderna on track to deliver 200 million doses of its covid vaccine to U.S. govt by end-June. According to today’s article on MarketWatch, "The U.S. government has an option to purchase up to 300 million doses of the Moderna vaccine. "

Moderna on track to deliver 200 million vaccine doses in U.S. by end of June. According to today’s article on MarketWatch, "The U.S. government has an option to purchase up to 300 million doses of the Moderna vaccine. "

Moderna says investing, adding staff to build up to 1 billion Covid-19 vaccine doses for 2021. According to today’s article on Business Insider, "The U.S. Government has agreed to purchase 200 million doses of the Moderna COVID-19 vaccine, with options for potential purchase of 300 million additional doses.", "On January 4, Moderna said it has increased its base-case global production estimate from 500 to 600 million doses for 2021."

Moderna’s Sales

Moderna’s sales growth is 1989.6% for the ongoing quarter and 19117.5% for the next. The company’s growth estimates for the present quarter and the next is 8.1% and 660%, respectively.

Moderna’s Revenue

Year-on-year quarterly revenue growth grew by 826.4%, now sitting on 246.7M for the twelve trailing months.

Volatility

Moderna’s last day, last week, and last month’s average volatility was 12.20%, 2.67%, and 0.77%, respectively.

Moderna’s last day, last week, and last month’s high and low average amplitude percentage was 7.42%, 6.03%, and 7.64%, respectively.

Moderna’s Stock Yearly Top and Bottom Value

Moderna’s stock is valued at $152.60 at 13:49 EST, way below its 52-week high of $178.50 and way above its 52-week low of $17.91.

Moderna’s Moving Average

Moderna’s value is way above its 50-day moving average of $131.30 and way above its 200-day moving average of $90.67.

Previous days news about Moderna

Moderna developing booster shot against strain first identified in South Africa. According to The Wall Street Journal on Monday, 25 January, "Even with the decrease, Moderna said, the vaccine-induced antibody response against the B.1.35 variant remained above levels that are expected to be protective. "

Moderna plans to test booster shot against South Africa strain. According to Bloomberg Quint on Monday, 25 January, "Even with the lower antibody levels, its existing vaccine should still protect against people who are exposed to the South Africa strain, Moderna said in a statement. ", "Meanwhile, Moderna said there was no reduction in antibodies against the rapidly spreading U.K. variant called B.1.1.7. "

Moderna: lab study confirms its Covid-19 vaccine still protects against new variants. According to MarketWatch on Monday, 25 January, "Shares of Moderna Inc. gained 4.6% in premarket trading on Monday afer the company said laboratory studies demonstrated that its COVID-19 vaccine can still protect people against two new coronavirus variants: the B.1.1.7 that was first identified in the United Kingdom, and the B.1.351 strain, out of South Africa. "

Moderna: study confirms Covid-19 vaccine protects against new variants. According to MarketWatch on Monday, 25 January, "Shares of Moderna Inc. gained 4.6% in premarket trading on Monday afer the company said laboratory studies demonstrated that its COVID-19 vaccine can still protect people against two new coronavirus variants: the B.1.1.7 that was first identified in the United Kingdom, and the B.1.351 strain, out of South Africa. "

Moderna climbs 12% after saying its coronavirus vaccine likely protects against new strains found in the UK and South Africa. According to Business Insider on Monday, 25 January, "In a press release, Moderna stated that its mRNA-1273 COVID-19 vaccine can probably protect people against variants of the disease first found in South Africa and the UK. ", "Shares of Moderna gained as much as 12% Monday following a report from the biotechnology company that its vaccine can likely protect against new mutant strains of the coronavirus. "

LEAVE A REPLY

Please enter your comment!
Please enter your name here